Prevalence_NN of_IN Blood-Borne_NP Infectious_NP Diseases_NPS in_IN Blood_NP Donors_NP in_IN Ghana_NP Transfusion-transmissible_NP infections_NNS among_IN 808_CD blood_NN donors_NNS in_IN Ghana_NP were_VBD investigated_VBN in_IN 1999_CD ._SENT Antibody_NN seroprevalences_NNS of_IN 3.8_CD ,_, 0.7_CD ,_, 8.4_CD ,_, and_CC 13.5_CD %_NN ,_, respectively_RB ,_, for_IN human_JJ immunodeficiency_NN virus_NN ,_, human_JJ T-cell_NN lymphotrophic_JJ virus_NN type_NN 1_CD ,_, hepatitis_NP C_NP virus_NN (_( HCV_NP )_) ,_, and_CC Treponema_NP pallidum_NN were_VBD obtained_VBN ._SENT The_DT seroprevalence_NN of_IN HCV_NP infection_NN was_VBD confirmed_VBN to_TO be_VB 0.9_CD %_NN after_IN supplementary_JJ testing_NN ,_, and_CC the_DT transfusion_NN risk_NN potential_NN of_IN these_DT pathogens_NNS was_VBD demonstrated_VBN ._SENT Although_IN blood_NN transfusion_NN saves_VBZ millions_NNS of_IN lives_NNS worldwide_RB each_DT year_NN ,_, recipients_NNS of_IN transfusions_NNS risk_VBP becoming_VBG infected_JJ with_IN blood-borne_VBN pathogens_NNS ._SENT Each_DT year_NN ,_, up_RB to_TO 4_CD million_CD blood_NN donations_NNS worldwide_RB are_VBP not_RB tested_VBN for_IN human_JJ immunodeficiency_NN virus_NN (_( HIV_NP )_) and_CC few_JJ are_VBP tested_VBN for_IN hepatitis_NP B_NP and_CC C_NP viruses_NNS (_( HBV_NP and_CC HCV_NP ,_, respectively_RB )_) ._SENT Virtually_RB none_NN are_VBP screened_VBN for_IN human_JJ T-cell_NN lymphotrophic_JJ virus_NN type_NN 1_CD (_( HTLV-1_NP )_) or_CC Treponema_NP pallidum_NP ,_, the_DT causative_JJ agent_NN of_IN syphilis_NN ._SENT Several_JJ studies_NNS have_VBP previously_RB indicated_VBN the_DT high_JJ prevalence_NN of_IN HBV_NP in_IN Ghana_NP ,_, and_CC prescreening_VBG of_IN blood_NN donors_NNS for_IN HBV_NP surface_NN antigen_NN (_( HBsAg_NP )_) is_VBZ thus_RB a_DT routine_JJ practice_NN ._SENT It_PP is_VBZ also_RB a_DT standard_JJ procedure_NN to_TO screen_VB Ghanaian_JJ blood_NN donors_NNS for_IN HIV_NP ._SENT HTLV-1_NP ,_, which_WDT causes_VBZ leukemia_NN ,_, was_VBD reported_VBN to_TO be_VB associated_VBN with_IN HIV-1-seropositive_JJ individuals_NNS in_IN Ghana_NP (_( -_: )_) ._SENT HCV_NP is_VBZ recognized_VBN as_IN the_DT primary_JJ cause_NN worldwide_RB of_IN transfusion-associated_JJ non-A-non-B_NN viral_JJ hepatitis_NN and_CC is_VBZ endemic_JJ in_IN West_NP Africa_NP ._SENT However_RB ,_, information_NN on_IN HCV_NP seroprevalence_NN in_IN Ghana_NP is_VBZ limited_VBN ,_, and_CC blood_NN donors_NNS are_VBP not_RB routinely_RB screened_VBN for_IN HCV_NP ._SENT T._NP pallidum_NP ,_, the_DT etiologic_JJ agent_NN of_IN syphilis_NN ,_, is_VBZ prevalent_JJ in_IN many_JJ African_JJ countries_NNS ,_, but_CC in_IN Ghana_NP ,_, data_NN on_IN T._NP pallidum_NN seroprevalence_NN are_VBP scanty_JJ ,_, with_IN antibodies_NNS thought_VBN to_TO occur_VB as_RB frequently_RB as_IN HBV_NP antibodies_NNS ._SENT This_DT study_NN was_VBD therefore_RB carried_VBN out_RP to_TO determine_VB the_DT current_JJ prevalence_NN of_IN HTLV-1_NP ,_, T._NP pallidum_NN ,_, and_CC particularly_RB HCV_NP in_IN Ghanaian_JJ blood_NN donors_NNS in_IN order_NN to_TO provide_VB information_NN for_IN appropriate_JJ policies_NNS ._SENT The_DT National_NP Blood_NP Transfusion_NP Service_NP of_IN Ghana_NP currently_RB selects_VBZ blood_NN donors_NNS on_IN the_DT basis_NN of_IN a_DT health_NN check_NN questionnaire_NN and_CC prescreening_NN for_IN HBsAg_NP ;_: donated_VBN blood_NN is_VBZ then_RB tested_VBN for_IN the_DT presence_NN of_IN HIV_NP antibodies_NNS ._SENT We_PP studied_VBD 3,131_CD individuals_NNS who_WP presented_VBD at_IN the_DT National_NP Blood_NP Transfusion_NP Service_NP ,_, Accra_NP ,_, Ghana_NP ,_, between_IN June_NP and_CC August_NP 1999_CD and_CC who_WP were_VBD routinely_RB tested_VBN for_IN HBsAg_NP with_IN a_DT latex_NN agglutination_NN test_NN kit_NN (_( Biotech_NP Laboratories_NPS Ltd._NP ,_, Suffolk_NP ,_, United_NP Kingdom_NP )_) ._SENT Of_IN these_DT donors_NNS who_WP were_VBD seronegative_JJ for_IN HBsAg_NP ,_, 808_CD were_VBD randomly_RB adopted_VBN as_IN study_NN subjects_NNS ._SENT Five_CD milliliters_NNS of_IN blood_NN was_VBD collected_VBN from_IN each_DT of_IN the_DT 808_CD donors_NNS ,_, labeled_VBN ,_, and_CC transported_VBN in_IN coolers_NNS to_TO the_DT Virology_NN Unit_NN at_IN the_DT Noguchi_NP Memorial_NP Institute_NP for_IN Medical_NP Research_NP ._SENT Sera_NP were_VBD then_RB analyzed_VBN for_IN antibodies_NNS to_TO HIV_NP ,_, HTLV-1_NP ,_, HCV_NP ,_, and_CC T._NP pallidum_NN with_IN SERODIA_NP passive-particle_NN agglutination_NN assay_NN kits_NNS (_( FUJIREBIO_NP Inc._NP ,_, Tokyo_NP ,_, Japan_NP )_) ._SENT Qualitative_JJ testing_NN protocols_NNS were_VBD applied_VBN according_VBG to_TO the_DT manufacturer_NN 's_POS instructions_NNS ,_, and_CC serum_NN dilutions_NNS were_VBD 1:16_CD for_IN HTLV-1_NP ,_, 1:32_CD for_IN HIV_NP and_CC HCV_NP ,_, and_CC 1:80_CD for_IN T._NP pallidum_NN ._SENT Supplementary_JJ tests_NNS were_VBD deemed_VBN necessary_JJ to_TO confirm_VB HCV_NP infection_NN ,_, as_IN the_DT samples_NNS were_VBD from_IN healthy_JJ ,_, asymptomatic_JJ individuals_NNS ._SENT Therefore_RB ,_, 68_CD samples_NNS shown_VBN by_IN the_DT SERODIA_NP assay_NN to_TO be_VB anti-HCV_NP positive_JJ at_IN a_DT 1:32_CD serum_NN dilution_NN were_VBD retested_VBN at_IN a_DT 1:400_CD serum_NN dilution_NN ,_, subjected_VBN to_TO the_DT HCV-SPOT_NP assay_NN (_( Genelabs_NP Diagnostics_NP Ltd._NP ,_, Singapore_NP )_) ,_, and_CC examined_VBD by_IN an_DT enzyme-linked_JJ immunoassay_NN (_( IMUCHECK-HCV_NP C50Ab_NP ;_: International_NP Reagents_NP Corporation_NP ,_, Kobe_NP ,_, Japan_NP )_) ._SENT Furthermore_RB ,_, a_DT third-generation_NN recombinant_JJ immunoblot_NN assay_NN (_( RIBA_NP 3_CD ;_: Ortho_NP Diagnostic_NP Systems_NP ,_, Roissy_NP ,_, France_NP )_) was_VBD applied_VBN ._SENT RIBA_NN 3_CD detects_VBZ antibodies_NNS to_TO five_CD structural_JJ and_CC nonstructural_JJ HCV_NP proteins_NNS (_( c100_NN ,_, c33c_NN ,_, c22p_NN ,_, NS5_NP ,_, and_CC superoxide_NN dismutase_NN )_) ,_, enabling_VBG the_DT determination_NN of_IN a_DT full_JJ immunoblot_NN profile_NN ._SENT Test_NN sera_NN were_VBD considered_VBN positive_JJ when_WRB at_IN least_JJS two_CD of_IN these_DT antibodies_NNS were_VBD detected_VBN ._SENT Reverse_JJ transcription-PCR_NN (_( RT-PCR_NP )_) was_VBD also_RB performed_VBN to_TO confirm_VB the_DT presence_NN of_IN the_DT HCV_NP genome_NN ._SENT HCV_NP RNA_NP in_IN the_DT sera_NN was_VBD identified_VBN by_IN a_DT nested_VBN RT-PCR_NP method_NN using_VBG primers_NNS derived_VBN from_IN the_DT 5_CD '_POS untranslated_JJ region_NN as_IN previously_RB described_VBN ._SENT The_DT majority_NN of_IN the_DT 808_CD blood_NN donors_NNS lived_VBD in_IN or_CC around_IN Accra_NP ,_, Ghana_NP ._SENT Thirty_CD (_( 3.7_CD %_NN )_) of_IN the_DT donors_NNS were_VBD regular_JJ voluntary_JJ donors_NNS ,_, and_CC 778_CD (_( 96.3_CD %_NN )_) were_VBD replacement_NN donors_NNS who_WP were_VBD family_NN members_NNS of_IN blood_NN recipients_NNS ._SENT As_IN shown_VBN in_IN Table_NP ,_, the_DT 21-to-25-year_JJ age_NN group_NN ,_, which_WDT included_VBD 212_CD (_( 26.2_CD %_NN )_) of_IN the_DT donors_NNS ,_, was_VBD the_DT largest_JJS ,_, followed_VBN by_IN the_DT 26-to-30-year_JJ age_NN group_NN ,_, with_IN 186_CD donors_NNS (_( 23.0_CD %_NN )_) ._SENT The_DT smallest_JJS group_NN was_VBD that_IN of_IN the_DT 56_CD to_TO 60_CD year_NN olds_NNS ,_, with_IN only_RB 2_CD donors_NNS (_( 0.2_CD %_NN )_) ._SENT Overall_RB ,_, 46_CD donors_NNS (_( 5.7_CD %_NN )_) were_VBD female_JJ and_CC 762_CD donors_NNS (_( 94.3_CD %_NN )_) were_VBD male_JJ ._SENT This_DT trend_NN of_IN male_JJ bias_NN is_VBZ a_DT regular_JJ feature_NN at_IN Ghanaian_JJ blood_NN donation_NN sites_NNS and_CC is_VBZ commonly_RB observed_VBN during_IN blood_NN donation_NN campaigns_NNS (_( J._NP Ansah_NP ,_, unpublished_JJ data_NNS )_) ._SENT TABLE_NN 1_CD |_SYM Age_NP distribution_NN and_CC seroprevalence_NN of_IN anti-HIV_NP ,_, anti-TP_NP ,_, anti-HTLV-1_JJ ,_, and_CC anti-HCV_NP in_IN blood_NN donors_NNS by_IN the_DT SERODIA_NP assays_VBZ The_DT HBV_NP seroprevalence_NN rate_NN for_IN the_DT study_NN period_NN was_VBD estimated_VBN to_TO be_VB 15.0_CD %_NN by_IN routine_JJ prescreening_NN ,_, as_RB 469_CD of_IN 3,131_CD individuals_NNS were_VBD seropositive_JJ for_IN HBsAg_NP ._SENT Seroprevalence_NN rates_NNS obtained_VBN by_IN screening_NN with_IN SERODIA_NP were_VBD as_RB follows_VBZ :_: for_IN anti-T_NN ._SENT pallidum_NN ,_, 13.5_CD %_NN (_( 109_CD were_VBD seropositive_JJ )_) ;_: for_IN anti-HCV_NP ,_, 8.4_CD %_NN (_( 68_CD were_VBD seropositive_JJ )_) ;_: for_IN anti-HIV_NP ,_, 3.8_CD %_NN (_( 31_CD were_VBD seropositive_JJ )_) ;_: and_CC for_IN anti-HTLV-1_JJ ,_, 0.7_CD %_NN (_( 6_CD were_VBD seropositive_JJ )_) ._SENT The_DT presence_NN of_IN anti-HCV_NP in_IN the_DT 68_CD sera_NN initially_RB found_VBD to_TO be_VB positive_JJ was_VBD confirmed_VBN as_RB follows_VBZ :_: 62_CD sera_NN were_VBD confirmed_VBN by_IN the_DT HCV-SPOT_NP assay_NN ,_, 7_CD sera_NN were_VBD confirmed_VBN by_IN RIBA_NP 3_CD ,_, 5_CD sera_NN were_VBD confirmed_VBN by_IN the_DT SERODIA_NP assay_NN (_( serum_NN dilution_NN ,_, 1:400_CD )_) ,_, and_CC 3_CD sera_NN were_VBD confirmed_VBN by_IN IMUCHECK_NP ._SENT Two_CD sera_NN were_VBD found_VBN to_TO be_VB HCV_NP positive_JJ by_IN RT-PCR_NP ._SENT The_DT reactivity_NN profiles_NNS for_IN samples_NNS that_WDT were_VBD found_VBN to_TO be_VB HCV_NP positive_JJ by_IN either_DT RIBA_NP 3_CD ,_, RT-PCR_NP ,_, or_CC the_DT SERODIA_NP (_( dilution_NN ,_, 1:400_CD )_) or_CC IMUCHECK_NP assay_NN are_VBP shown_VBN in_IN Table_NP ._SENT TABLE_NN 2_CD |_SYM Reactivity_NN profiles_NNS for_IN seven_CD subjects_NNS positive_JJ for_IN anti-HCV_NP by_IN either_DT RIBA_NP 3_CD ,_, PCR_NP ,_, the_DT SERODIA_NP assay_NN ,_, or_CC the_DT HCV-SPOT_NP assay_NN The_DT 15_CD %_NN HBV_NP seroprevalence_NN level_NN indicated_VBN by_IN the_DT HBsAg_NP prescreening_NN data_NNS for_IN the_DT 3-month_JJ duration_NN of_IN the_DT investigation_NN is_VBZ similar_JJ to_TO the_DT previously_RB reported_VBN HBsAg_NP seroprevalence_NN of_IN 15.8_CD %_NN ._SENT The_DT current_JJ transfusion_NN transmission_NN risk_NN potential_NN in_IN Ghana_NP for_IN HTLV-1_NP ,_, HCV_NP ,_, and_CC T._NP pallidum_NN is_VBZ illustrated_VBN by_IN the_DT data_NNS presented_VBN in_IN Table_NP ._SENT Total_JJ seroprevalence_NN levels_NNS were_VBD highest_RBS in_IN the_DT age_NN groups_NNS (_( 21_CD to_TO 36_CD years_NNS )_) corresponding_JJ to_TO those_DT described_VBN as_IN the_DT most_RBS sexually_RB active_JJ ._SENT The_DT highest_JJS seroprevalence_NN observed_VBD was_VBD for_IN anti-T_NP ._SENT pallidum_NP (_( 13.5_CD %_NN )_) ._SENT This_DT corresponds_VBZ with_IN the_DT results_NNS of_IN previous_JJ studies_NNS of_IN sexually_RB transmitted_VBN diseases_NNS in_IN Ghana_NP ,_, where_WRB T._NP pallidum_NP and_CC HBV_NP were_VBD noted_VBN as_IN the_DT most_RBS frequently_RB occurring_VBG pathogens_NNS ._SENT The_DT seroprevalence_NN of_IN the_DT anti-HTLV-1_JJ antibody_NN was_VBD found_VBN to_TO be_VB 0.7_CD %_NN ,_, and_CC the_DT antibody_NN was_VBD detected_VBN in_IN male_JJ blood_NN donors_NNS under_IN 40_CD years_NNS of_IN age_NN ._SENT The_DT low_JJ HTLV-1_JJ seroprevalence_NN obtained_VBN by_IN our_PP$ study_NN confirms_VBZ the_DT earlier_JJR observation_NN of_IN low_JJ HTLV-1_JJ antibody_NN levels_NNS in_IN Ghana_NP ._SENT Previously_RB ,_, HTLV-1_NP antibodies_NNS were_VBD associated_VBN with_IN HIV_NP and_CC HCV_NP infections_NNS ,_, and_CC 19_CD %_NN of_IN the_DT dual_JJ infections_NNS observed_VBN in_IN our_PP$ study_NN involved_VBN HTLV-1_NP (_( one_CD case_NN with_IN HIV_NP ,_, three_CD cases_NNS with_IN HCV_NP )_) ._SENT The_DT 3.8_CD %_NN seroprevalence_NN level_NN obtained_VBN for_IN HIV_NP vindicates_VBZ the_DT screening_NN of_IN donated_VBN blood_NN for_IN HIV_NP ,_, and_CC the_DT national_JJ seroprevalence_NN of_IN HIV_NP was_VBD estimated_VBN to_TO be_VB 3_CD %_NN in_IN 2001_CD ._SENT HIV_NP was_VBD involved_VBN in_IN 59_CD %_NN of_IN the_DT multiple_JJ infections_NNS recorded_VBN and_CC was_VBD a_DT major_JJ dual_JJ infection_NN with_IN T._NP pallidum_NN ._SENT Use_NN of_IN the_DT SERODIA_NP or_CC HCV-SPOT_NP assay_NN resulted_VBD in_IN a_DT high_JJ rate_NN of_IN anti-HCV_NP false-positive_JJ results_NNS ,_, which_WDT were_VBD resolved_VBN by_IN supplementary_JJ assay_NN (_( especially_RB RIBA_NP 3_CD )_) ,_, and_CC overall_RB ,_, HCV_NP seroprevalence_NN was_VBD 0.9_CD %_NN ._SENT Other_JJ reports_NNS on_IN anti-HCV_NP seroprevalence_NN in_IN Ghana_NP ,_, determined_VBN by_IN screening_NN assays_NNS ,_, found_VBD seroprevalence_NN rates_NNS of_IN 5.4_CD %_NN in_IN children_NNS ,_, 2.8_CD %_NN in_IN adults_NNS ,_, and_CC 5.2_CD %_NN in_IN blood_NN donors_NNS ._SENT Supplemental_JJ tests_NNS such_JJ as_IN RIBA_NP 3_CD are_VBP necessary_JJ to_TO confirm_VB the_DT presence_NN of_IN HCV_NP infection_NN in_IN asymptomatic_JJ Ghanaians_NNS ._SENT The_DT presence_NN of_IN HCV_NP in_IN the_DT blood_NN is_VBZ indicated_VBN by_IN positive_JJ detection_NN by_IN RT-PCR_NP ,_, and_CC our_PP$ data_NNS showed_VBD two_CD active_JJ cases_NNS of_IN HCV_NP infection_NN among_IN the_DT blood_NN donors_NNS ._SENT In_IN conclusion_NN ,_, this_DT study_NN illustrates_VBZ the_DT current_JJ transfusion-transmissible_JJ risk_NN of_IN T._NP pallidum_NP ,_, HTLV-1_NP ,_, and_CC HCV_NP in_IN Ghana_NP ._SENT It_PP is_VBZ recommended_VBN that_IN routine_JJ blood_NN screening_VBG prior_RB to_TO transfusion_NN should_MD include_VB tests_NNS for_IN anti-HCV_NP and_CC anti-T_NP ._SENT pallidum_NN antibodies_NNS ._SENT Developing_VBG appropriate_JJ methods_NNS for_IN HCV_NP diagnosis_NN will_MD require_VB an_DT evaluation_NN of_IN the_DT cost-effectiveness_NN of_IN general_JJ screening_NN and/or_CC supplementary_JJ assays_NNS of_IN donated_VBN blood_NN ._SENT Periodic_JJ studies_NNS to_TO investigate_VB transfusion-transmissible_JJ infectious_JJ diseases_NNS are_VBP required_VBN to_TO enable_VB safety_NN reviews_NNS of_IN the_DT blood_NN supply_NN ._SENT 